Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
NCT07428746
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength. Participants will: Receive GLP-1 RA therapy as part of their routine clinical care Complete muscle strength assessments (hand grip strength, Timed Up and Go test) Provide blood samples for bone turnover markers Undergo bone mineral density testing
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Diabetes Mellitus, Type 2
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 65 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Emory University
- Last updated on ClinicalTrials.gov
- August 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 1
- Grady Memorial Hospital · Atlanta, GA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.